Glucose control during acute myocardial infarction.
The need for tight glycaemic control in the immediate aftermath of myocardial infarction is controversial. Trials of glucose-insulin-potassium (GIK) therapy, given without regard to glucose levels, have only confused the issue. Despite considerable clinical interest, only three randomized controlled trials have, as their primary goal, aimed to determine whether better glycaemic control improves the outcomes of myocardial infarction. This review examines the results of these trials and other data to support the case for tight glycaemic control in patients with myocardial infarction.
Cheung
N W
NW
Centre for Diabetes and Endocrinology Research, Westmead Hospital, New South Wales, Australia. wah@westgate.wh.usyd.edu.au
D001786:Blood Glucose / Q000378:metabolism*; D006801:Humans; D006943:Hyperglycemia / Q000097:blood / Q000401:mortality / Q000628:therapy; D009203:Myocardial Infarction / Q000097:blood* / Q000401:mortality / Q000628:therapy*; D016032:Randomized Controlled Trials as Topic / Q000379:methods
D001786:Blood Glucose